Ipratropium Adultes Cristers

Ipratropium bromide, the active ingredient in Ipratropium Adultes Cristers, is an anticholinergic (muscarinic antagonist) presented as an inhalation formulation for inhalation use. It is employed to relieve bronchospasm and reduce airway secretions in patients with obstructive lung diseases such as COPD and asthma.

GNH USA supplies Ipratropium Adultes Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Ipratropium bromide is used as a bronchodilator in obstructive airway diseases, improving airflow and reducing secretions.

- Chronic Obstructive Pulmonary Disease (COPD): improves lung function and decreases bronchial mucus production in COPD patients. - Asthma (adjunct therapy): provides additional bronchodilation when combined with beta‑agonists for patients with persistent bronchospasm. - Bronchospasm of other obstructive conditions: reduces airway resistance and eases breathing during acute episodes. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity in patients with COPD or asthma.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to its anticholinergic activity in the airways.

Common Side Effects: - Dry mouth - Cough - Throat irritation - Headache - Dizziness

Serious or Rare Side Effects: - Paradoxical bronchospasm - Angioedema - Severe allergic reaction (anaphylaxis)

Before prescribing ipratropium bromide, clinicians should evaluate patient history and monitor for potential complications associated with anticholinergic therapy.

- Assess respiratory status: confirm diagnosis of COPD or asthma and baseline lung function. - Monitor for paradoxical bronchospasm: discontinue if severe worsening of breathing occurs. - Avoid use in patients with hypersensitivity: contraindicated in those with known allergy to ipratropium or formulation components. - Use with caution in narrow‑angle glaucoma: anticholinergic effect may increase intra‑ocular pressure. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medications, altering anticholinergic load or bronchodilator response.

Major Interactions (Avoid): - Concurrent use with other muscarinic antagonists (e.g., tiotropium): risk of excessive anticholinergic effects. - Combination with MAO inhibitors: may increase risk of hypertensive reactions.

Moderate Interactions (Monitor Closely): - Beta2‑agonists (e.g., albuterol): additive bronchodilation may require dose adjustment. - Antihistamines: may enhance dry‑mouth sensation. - Theophylline: monitor serum levels as ipratropium may affect metabolism.